Myocardial Fibrosis - Pipeline Review, H2 2019

December 2019 | 89 pages | ID: M97F3D3785CEN
Global Markets Direct

Abstracts

Myocardial Fibrosis - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2019, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 10 and 3 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
• The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Myocardial Fibrosis - Overview
Myocardial Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Myocardial Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Myocardial Fibrosis - Companies Involved in Therapeutics Development
Ember Therapeutics Inc (Inactive)
Evotec SE
Galectin Therapeutics Inc
Haya Therapeutics
Invivosciences Inc
Lead Discovery Center GmbH
Liminal BioSciences Inc
MandalMed Inc
Merck & Co Inc
NovoMedix LLC
Palatin Technologies Inc
Pharmaxis Ltd
TRACON Pharmaceuticals Inc
Vectus Biosystems Ltd
Myocardial Fibrosis - Drug Profiles
Antisense Oligonucleotides for Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
belapectin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BMP-7 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Tissue Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GYY-4137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NM-922 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PL-5028 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PN1-Ab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5153A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5338K - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5382A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPI-2049 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TRC-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-0004 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Myocardial Fibrosis - Dormant Projects
Myocardial Fibrosis - Discontinued Products
Myocardial Fibrosis - Product Development Milestones
Featured News & Press Releases
Oct 08, 2019: Publication that demonstrates reversal of established fibrosis in a preclinical model of cardiac fibrosis by VIP
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Myocardial Fibrosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Myocardial Fibrosis - Pipeline by Ember Therapeutics Inc (Inactive), H2 2019
Myocardial Fibrosis - Pipeline by Evotec SE, H2 2019
Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2019
Myocardial Fibrosis - Pipeline by Haya Therapeutics, H2 2019
Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2019
Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2019
Myocardial Fibrosis - Pipeline by Liminal BioSciences Inc, H2 2019
Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2019
Myocardial Fibrosis - Pipeline by Merck & Co Inc, H2 2019
Myocardial Fibrosis - Pipeline by NovoMedix LLC, H2 2019
Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, H2 2019
Myocardial Fibrosis - Pipeline by Pharmaxis Ltd, H2 2019
Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2019
Myocardial Fibrosis - Pipeline by Vectus Biosystems Ltd, H2 2019
Myocardial Fibrosis - Dormant Projects, H2 2019
Myocardial Fibrosis - Discontinued Products, H2 2019

List Of Figures

LIST OF FIGURES

Number of Products under Development for Myocardial Fibrosis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Top 10 Targets, H2 2019
Number of Products by Stage and Top 10 Targets, H2 2019
Number of Products by Top 10 Mechanism of Actions, H2 2019
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019

COMPANIES MENTIONED

Ember Therapeutics Inc (Inactive)
Evotec SE
Galectin Therapeutics Inc
Haya Therapeutics
Invivosciences Inc
Lead Discovery Center GmbH
Liminal BioSciences Inc
MandalMed Inc
Merck & Co Inc
NovoMedix LLC
Palatin Technologies Inc
Pharmaxis Ltd
TRACON Pharmaceuticals Inc
Vectus Biosystems Ltd